LALPATHLABDr. Lal Pathlabs Ltd.
Dr. Lal Pathlabs declares ₹5 interim dividend and invests ₹49.5 crore in Dubai unit
- Mergers & acquisitions
- Diagnostics
Reviewed byRachit TripathiBlacklitt Research
Dr. Lal Pathlabs (NSE: LALPATHLAB) declared a 2nd interim dividend of ₹5 a share and approved up to ₹49.5 crore of further investment in its Dubai subsidiary, it said in a filing on 04 Nov 2026. The board also appointed Vasuta Agarwal as an additional independent director, subject to member approval by postal ballot.
Key highlights
- Dividend: ₹5 per share, 50% of ₹10 face value
- Record date: 11 Nov 2026
- Further investment in LPL Dubai: up to ₹49.5 crore
- Of which up to ₹30 crore for Sunshine Healthcare, Ghana
The board decisions in numbers
| Item | Detail |
|---|---|
| Dividend | 2nd interim dividend of ₹5 per share for FY 2026-27 |
| Record date | 11 Nov 2026 |
| Payment | Within 30 days of declaration |
| Investment | Up to ₹49.5 crore in Dr. Lal PathLabs FZCO, Dubai, in one or more tranches |
| Ghana portion | Up to ₹30 crore for further investment in Sunshine Healthcare Limited |
| Expected completion | By 31 Mar 2027, or other mutually agreed dates |
| Director | Vasuta Agarwal, Non-Executive Independent Director, three years from 04 Nov 2026 |
The 2nd interim dividend
The board declared a 2nd interim dividend of ₹5 per equity share for FY 2026-27, which the company states is 50% of the ₹10 face value. The record date is 11 Nov 2026, and the company says payment will be made within 30 days of declaration.
The company's quarter ended 30 Sep 2026 reported standalone profit of ₹179.7 crore and consolidated profit of ₹193.9 crore, with auditors Deloitte Haskins & Sells LLP issuing an unmodified limited review conclusion on both.
Investment in the Dubai subsidiary
Dr. Lal PathLabs FZCO, Dubai, was incorporated on 12 Jun 2026 to make strategic investments in diagnostics and allied activities. The company says the proposed investment is for its business and operational requirements, including further investment in Sunshine Healthcare Limited, Ghana, which provides healthcare and diagnostics services.
The transaction is a related party transaction between wholly owned subsidiaries, and the company says it will be on an arm's length basis. The Dubai unit will remain a wholly owned subsidiary of the company.
A new independent director
Vasuta Agarwal is Chief Revenue Officer at Gnani.ai and sits on the boards of IndiaMART InterMESH Limited, Kaya Limited, Iglulabs Software Private Limited and Valetez Services Private Limited.
Her appointment is effective from 04 Nov 2026 but is subject to approval by members through postal ballot.
What the board decisions mean for Dr. Lal Pathlabs' shareholders
The dividend is a cash payment of ₹5 a share with a record date of 11 Nov 2026. The company's latest quarter, reported in the same filing, was profitable on both standalone and consolidated bases, and the company also reported a recent acquisition of 70% of SN Genelab Private Limited for up to ₹168 crore plus an earn-out.
The filing does not say how the ₹49.5 crore investment will be funded, what regulatory approvals are needed in Ghana or the UAE, or what effect it will have on the company's results. Whether the postal ballot approval of the director has been obtained is also not stated. The next dated step is the record date of 11 Nov 2026.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
